Tradestie Institutional Equity Comparison Engine
EVGN vs ANRO โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ANRO Overall Edge
ANRO Captures Institutional Edge (3โ0 Pillars ยท 6โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Alto Neuroscience Inc. (ANRO) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, EVGN trades at N/M Forward P/E with -858.2% operating margin (-60.7% YoY revenue) versus ANRO at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, EVGN sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ANRO sits in BREAKDOWN (9th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
EVGN N/M vs ANRO N/M Fwd P/E
Growth & Margin Winner
ANRO
Op Margin -858.2% vs 0.0% ยท YoY -60.7% vs +0.0%
Momentum & Technical Winner
ANRO
1Y -71.9% vs +105.7% ยท 52W Pos 9% vs 53%
Options & Structure Winner
ANRO
UNCLASSIFIED (N/A IV) vs BREAKDOWN (9th %ile IV)
EVGN
NASDAQ
Evogene Ltd.
Agricultural Chemicals
$0.34
-13.17% 1D
Market Cap
$6.0M
1M Return
-7.58%
1Y Return
-71.89%
Forward P/E
N/M
Unified AI Score
44.1 / 100
HOLD
Tech 42.0
Fund 44.0
Flow 50.0
Mom 60.0
ANRO
NYSE
Alto Neuroscience Inc.
Pharmaceutical Preparations
$24.91
-8.15% 1D
Market Cap
$1.1B
1M Return
+9.16%
1Y Return
+105.7%
Forward P/E
N/M
Unified AI Score
34.3 / 100
SELL
Tech 15.0
Fund 38.0
Flow 64.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
EVGN -71.89%
ANRO +105.7%
Spread: +177.59 pp (ANRO Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
EVGN TTM Op. Margin: -858.2%
ANRO TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on EVGN vs ANRO. Trailing 12-month operating profitability (EVGN -858.2% vs ANRO 0.0%) and valuation multiples (EVGN N/M vs ANRO N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | EVGN | ANRO | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $6.0M | $1.1B | Larger Scale | ANRO |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | -60.7% | +0.0% | Higher Growth | ANRO |
| Operating Margin (TTM) Profitability | -858.2% | 0.0% | Higher Margin | ANRO |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -182.8% | -46.7% | Higher ROE | ANRO |
| 52-Week Range Position Momentum | 9% ($0โ$1) | 53% ($11โ$37) | Stronger Trend | ANRO |
| Beta / 30D Volatility Risk Regime | 1.37ฮฒ ยท 138% Vol | 2.03ฮฒ ยท 94% Vol | Lower Realized Risk | ANRO |
| Unified Institutional Score Composite Signal | 44.1 / 100 (HOLD) | 34.3 / 100 (SELL) | Higher Composite | EVGN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full EVGN vs ANRO Buy Guide
EVGN
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ANRO
BREAKDOWN
58d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
9th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither EVGN nor ANRO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.